Hans Robert Schönherr's scientific contributions
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (3)
Diabetes mellitus affects 9% of the adult population worldwide and the economic burden of the disease is growing exponentially. In type 2 diabetes mellitus (T2DM), when life style interventions fail to achieve treatment targets, oral antidiabetic drugs are prescribed to improve glycemic control. Several new oral antidiabetics have been launched in...
Recent meta-analyses revealed an association between type 2 diabetes mellitus (T2DM) and cancer. The strongest relationship was demonstrated for liver and pancreatic cancer, followed by endometrial cancer. We aimed at assessing the association between T2DM and cancer specifically for Tyrolean patients.
We investigated cancer incidence in Tyrolean s...
Citations
... Metformin is indicated as a first-line glucose lowering agent for patients with type 2 diabetes mellitus (T2DM), 1 though it has been frequently associated with gastrointestinal symptoms than most other oral glucose lowering agents. 2,3 Moreover, although metformin is still recommended as a drug of choice for patients with T2DM, [4][5][6] there are increasing reports demanding a more personalized approaches in its use. 7,8 Previous studies reported that the variability to metformin treatment associated incidence of side effects is related to differences in individual genetic profile. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/320299751411714-1453376819633_Q64/Lukas-Lunger.jpg)
... 6 One potential source of bias is the temporal sequence of the diagnoses, and, therefore, it is important to assess the link between these two conditions over time. [7][8][9] Some studies have evaluated the temporal relationship, but the results have been inconsistent. A study by Lega et al. (2016) demonstrated that the diagnosis of type 2 diabetes was associated with elevated risks of pancreatic, endometrial, liver, and thyroid cancers during the first 3 months as well as up to 10 years after the onset of diabetes. ...
